Cuomo announces U.S.-Cuba venture to develop new cancer treatments

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

New York Governor Andrew Cuomo announced Roswell Park Comprehensive Cancer Center has formed the Innovative Immunotherapy Alliance S.A., the first-ever biotech venture between the U.S. and Cuba.

The joint venture gives Roswell Park access to CIMAvax and three Cuban-developed cancer immunotherapy treatments not previously accessible to U.S. patients or researchers: IL-2 mutein, VSSP and another investigational immunotherapy that targets tumor-associated gangliosides.

While these agents are still investigational therapies in the U.S., evidence to date strongly suggests that all four are worthy of further study in several cancer types.

This joint venture biotech company, Innovative Immunotherapy Alliance S.A., will be based in Cuba and will be operated jointly by CIM’s commercial affiliate, CIMAB S.A., and by a Roswell Park subsidiary, GBCT II LLC.

This initiative will move forward in accordance with permissions issued by the Office of Foreign Assets Control of the Department of Treasury, the Bureau of Industry and Security of the U.S. Department of Commerce and the U.S. FDA.

Roswell Park expects to initiate additional clinical trials, enrolling more than 100 patients in the U.S. within the next three years with plans for additional clinical studies to follow. Nearly $4 million in donations is funding Roswell Park’s initial CIMAvax clinical trials.

Aside from CIMAvax, these cancer drugs have never been studied before in U.S. patients. The Cuban phase II and phase III clinical trials of CIMAvax have shown increased overall survival and improvement in quality of life for patients with non-small cell lung cancer.

Table of Contents

YOU MAY BE INTERESTED IN

Despite steady progress in reducing overall cancer mortality rates, cancer incidence in women is rising, according to the American Cancer Society’s “Cancer Statistics, 2025” report. Incidence rates in women 50-64 years of age have surpassed those in men, and rates in women under 50 are now 82% higher than their male counterparts, up from 51% higher in 2002. In 2021, for the first time, lung cancer incidence was higher in women under 65 than in men. 
Over the past five years, Cedars-Sinai Cancer has built an integrated, regional system designed to provide cancer care close to where patients live and work. This model of care, directed by an academic medical center to patients at the community level, proved to be the best possible approach to supporting patients in our 11-million-person catchment area during the worst fire disaster in California history. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login